Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease.

about

Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease.

Item

http://www.wikidata.org/entity/Q52559905

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Medical Treatment Options for ...... and/or Leptomeningeal Disease.

@en

Medical Treatment Options for ...... and/or Leptomeningeal Disease.

@nl

type

Item

label

Medical Treatment Options for ...... and/or Leptomeningeal Disease.

@en

Medical Treatment Options for ...... and/or Leptomeningeal Disease.

@nl

prefLabel

Medical Treatment Options for ...... and/or Leptomeningeal Disease.

@en

Medical Treatment Options for ...... and/or Leptomeningeal Disease.

@nl

P1476

Medical Treatment Options for ...... and/or Leptomeningeal Disease.

@en

P2093

Maximilian Hochmair

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

P2888

s11523-018-0566-1

P304

269-285

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S11523-018-0566-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29700687

http://www.w3.org/2001/XMLSchema#string

P921

Meningeal carcinomatosis

brain neoplasm

membrane proteins

Anzim

P932

6004273

http://www.w3.org/2001/XMLSchema#string